![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Beacon will be responsible for the development and commercialization of AAV204 capsid for potential use for the treatment of retinal diseases.
Lead Product(s): AAV204
Therapeutic Area: Ophthalmology Product Name: AAV204
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Beacon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 11, 2024
Details:
The proceeds will fund preparations for resubmission of Abeona's BLA and for commercialization of pz-cel (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets in development for recessive dystrophic epidermolysis bullosa.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Stifel
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2024
Details:
EB-101 (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets, is being developed for the treatment of recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder caused by a defect in the COL7A1 gene.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
EB-101 (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets, is being developed for the treatment of recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder caused by a defect in the COL7A1 gene.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
The proceeds will support the Abeona’s ongoing preparations for launch and commercialization of EB-101 (prademagene zamikeracel), an investigational autologous, COL7A1 gene-corrected epidermal sheets for the treatment of recessive dystrophic epidermolysis bullosa.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Avenue Venture Opportunities Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 08, 2024
Details:
EB-101 (prademagene zamikeracel), Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets, is being developed for the treatment of recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder caused by a defect in the COL7A1 gene.
Lead Product(s): Prademagene Zamikeracel
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa, clinical efficacy and safety data appear adequate to support a BLA submission.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
EB-101, its investigational autologous, engineered cell therapy, for patients with recessive dystrophic epidermolysis bullosa, clinical efficacy and safety data appear adequate to support a BLA submission.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
EB-101 is an autologous, engineered cell therapy for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder without an approved treatment, in which patients suffer with severe epidermal wounds that impact the length and quality of their lives.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
Abeona will use the net proceeds primarily to fund the preparations for commercialization of its product candidate EB-101, an investigational autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa.
Lead Product(s): EB-101
Therapeutic Area: Genetic Disease Product Name: EB-101
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Nantahala Capital Management
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 07, 2023